Familial Mediterranean fever (FMF) & hereditary periodic fever syndromes (autoinflammatory)
Bedside summary
The commonest monogenic autoinflammatory disease — autosomal recessive MEFV (pyrin) mutation, most frequent in Mediterranean, Middle-Eastern, Armenian, Turkish, Sephardic Jewish and some Indian populations. Recurrent self-limiting attacks (12-72 h) of FEVER with serositis: sterile peritonitis (severe abdominal pain mimicking surgical abdomen), pleuritis, synovitis (monoarthritis) and an erysipelas-like rash on the lower leg/ankle. Attacks resolve spontaneously but recur. The major long-term threat is AA (secondary) amyloidosis causing renal failure. Lifelong colchicine both prevents attacks and prevents amyloidosis. (Other periodic fevers: TRAPS, CAPS, HIDS/MKD, PFAPA — considered when colchicine fails or in non-FMF ethnicities.)
Red flags
- First presentation with acute abdomen — do not assume FMF; exclude surgical cause before labelling
- New proteinuria/nephrotic syndrome/renal impairment — AA amyloidosis (the key long-term threat)
- Colchicine overdose features (profuse diarrhoea, vomiting, pancytopenia, multi-organ failure) — potentially fatal, even small excess
- Severe toxicity when colchicine combined with clarithromycin/statins/ciclosporin
- Attacks every month despite maximal colchicine — colchicine resistance, needs IL-1 blockade
Assessment
Differential diagnosis
- Acute surgical abdomen (appendicitis, perforation) — FMF peritonitis is sterile but mimics it; past identical self-limiting episodes are the clue
- Other periodic fevers: TRAPS (longer attacks, periorbital oedema), CAPS (cold-induced urticaria, deafness), HIDS/mevalonate kinase deficiency (high IgD, cervical nodes), PFAPA
- Adult-onset Still disease (quotidian fever, evanescent rash, very high ferritin)
- Systemic JIA; cyclical/recurrent infection; inflammatory bowel disease
- Acute intermittent porphyria (recurrent abdominal pain)
Investigations
- MEFV genetic testing (confirms FMF; M694V = severe phenotype/higher amyloid risk)
- Acute-phase reactants DURING and BETWEEN attacks: CRP, ESR, SAA (serum amyloid A — key for amyloid risk), fibrinogen
- FBC (neutrophilia during attack); exclude surgical/infective cause (lactate, imaging) on first presentation
- Urinalysis for PROTEINURIA + urine protein:creatinine — surveillance for AA amyloidosis (renal)
- IgD / mevalonate kinase, and gene panel if atypical/colchicine-resistant (other periodic fevers)
Management
- Recognise the pattern: recurrent short febrile serositis attacks + compatible ethnicity + family history; confirm with MEFV genetics
- On first acute attack exclude a true surgical/infective abdomen before attributing to FMF
- Acute attack: supportive — NSAIDs/analgesia; colchicine does NOT abort an established attack but is continued
- Start lifelong daily COLCHICINE — prevents attacks AND prevents amyloidosis; do not stop even if attacks controlled (amyloid protection)
- Uptitrate colchicine to maximum tolerated dose; counsel strict adherence; monitor for diarrhoea/myopathy and interactions (clarithromycin, statins, ciclosporin — colchicine toxicity)
- Colchicine resistance (>=1 attack/month on max tolerated dose for 6 months) or intolerance: add IL-1 inhibitor (anakinra or canakinumab)
- Monitor SAA/CRP between attacks and urine protein — target normalised SAA to prevent amyloidosis
- Genetic counselling; consider other periodic fever syndromes if colchicine ineffective or non-FMF ethnicity
Drugs & doses
Disposition
Complications & pitfalls
- AA (secondary) amyloidosis -> nephrotic syndrome and end-stage renal failure (main cause of mortality)
- Chronic arthritis; infertility/subfertility (improved by colchicine)
- Peritoneal adhesions from recurrent serositis
- Colchicine toxicity (especially with interacting drugs/renal impairment)
Exam pearls
- Colchicine is lifelong and prevents amyloidosis — never stop it just because attacks are controlled; adherence is the single most important determinant of outcome.
- Colchicine does not abort an established attack — it is prophylactic; manage the acute attack with analgesia/NSAIDs.
- Monitor serum amyloid A (SAA) and urine protein — persistently high SAA signals ongoing amyloid risk even if asymptomatic.
- IL-1 inhibitors (anakinra/canakinumab) are the answer for colchicine resistance (EULAR/PReS 2016, updated 2025).
- Beware fatal colchicine toxicity with clarithromycin, statins, ciclosporin and in renal impairment — adjust/avoid.
- On a first 'surgical' abdomen in a young person of relevant ethnicity with prior identical self-limiting episodes, think FMF.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.